On September 1, 2026, Ocugen announced the first patient was dosed in the global Phase 3 registrational trial of OCU410, a gene therapy candidate for Geographic Atrophy secondary to dry age-related macular degeneration. This follows FDA alignment on pivotal trial design and RMAT designation granted in July 2026. Separately, on September 3, 2026, the independent Data Monitoring Committee recommended continuing the Phase 2/3 OCU410ST trial for Stargardt disease to obtain eight-month follow-up data on the entire population, despite interim results showing a negative direction of treatment effect that could suggest futility. Ocugen operates in the biotechnology industry and develops gene therapies for inherited retinal diseases.

Ocugen reported a net loss of $0.07 per share for the quarter ended June 30, 2026, with operating expenses rising to $17.9 million from $15.2 million in the prior year period. The company closed a $130.0 million convertible senior notes financing, generating approximately $112.5 million in net proceeds, which it used to fully retire its Avenue Capital loan and extend its cash runway into 2028. Cash reserves increased to $100.4 million as of June 30, 2026. Clinically, Ocugen received FDA clearance to initiate the Phase 3 ArMaDa trial for OCU410 in geographic atrophy and was granted RMAT designation for the same program. The company also signed a binding term sheet with Roots Pharmaceutical for an exclusive license of OCU400 in the MENA region, featuring up to $255 million in sales milestones. Ocugen appointed Mohamed Genead as Chief Medical Officer and Chris Clark as Head of Corporate Communications. Ocugen is a biotechnology company developing gene therapies for blindness diseases.

Ocugen, Inc. signed a binding term sheet for the licensing of its OCU400 modifier gene therapy for retinitis pigmentosa within the Middle East and North Africa region. Ocugen, Inc. is a biotechnology company focused on developing and commercializing gene therapies for ocular diseases.